CA3218258A1 - Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists - Google Patents
Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists Download PDFInfo
- Publication number
- CA3218258A1 CA3218258A1 CA3218258A CA3218258A CA3218258A1 CA 3218258 A1 CA3218258 A1 CA 3218258A1 CA 3218258 A CA3218258 A CA 3218258A CA 3218258 A CA3218258 A CA 3218258A CA 3218258 A1 CA3218258 A1 CA 3218258A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- ring
- 6alkyl
- methyl
- occurrence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/091510 | 2021-04-30 | ||
| CN2021091510 | 2021-04-30 | ||
| PCT/US2022/026832 WO2022232459A1 (en) | 2021-04-30 | 2022-04-28 | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3218258A1 true CA3218258A1 (en) | 2022-11-03 |
Family
ID=81748636
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3218258A Pending CA3218258A1 (en) | 2021-04-30 | 2022-04-28 | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250230140A1 (https=) |
| EP (1) | EP4330249A1 (https=) |
| JP (1) | JP2024517769A (https=) |
| KR (1) | KR20240044386A (https=) |
| CN (1) | CN117751106A (https=) |
| AU (1) | AU2022264579A1 (https=) |
| CA (1) | CA3218258A1 (https=) |
| IL (1) | IL308035A (https=) |
| MX (1) | MX2023012830A (https=) |
| WO (1) | WO2022232459A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023109878A1 (zh) * | 2021-12-15 | 2023-06-22 | 武汉人福创新药物研发中心有限公司 | 三氮唑类lpar1拮抗剂及其用途 |
| WO2025051267A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
| WO2025051266A1 (zh) * | 2023-09-08 | 2025-03-13 | 西藏海思科制药有限公司 | 杂芳环衍生物的lpar1拮抗剂及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019126084A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists |
| JP7208240B2 (ja) * | 2017-12-19 | 2023-01-18 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアジン |
| ES2946657T3 (es) * | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| CN111434655A (zh) * | 2019-01-15 | 2020-07-21 | 武汉朗来科技发展有限公司 | 溶血磷脂酸受体拮抗剂及其制备方法 |
| WO2020257135A1 (en) * | 2019-06-18 | 2020-12-24 | Bristol-Myers Squibb Company | Triazole carboxylic acids as lpa antagonists |
| WO2022034568A1 (en) * | 2020-08-11 | 2022-02-17 | Viva Star Biosciences Limited | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists |
-
2022
- 2022-04-28 CN CN202280040512.3A patent/CN117751106A/zh active Pending
- 2022-04-28 IL IL308035A patent/IL308035A/en unknown
- 2022-04-28 EP EP22724318.5A patent/EP4330249A1/en active Pending
- 2022-04-28 AU AU2022264579A patent/AU2022264579A1/en active Pending
- 2022-04-28 CA CA3218258A patent/CA3218258A1/en active Pending
- 2022-04-28 MX MX2023012830A patent/MX2023012830A/es unknown
- 2022-04-28 US US18/557,918 patent/US20250230140A1/en active Pending
- 2022-04-28 WO PCT/US2022/026832 patent/WO2022232459A1/en not_active Ceased
- 2022-04-28 JP JP2023566850A patent/JP2024517769A/ja active Pending
- 2022-04-28 KR KR1020237041165A patent/KR20240044386A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022232459A1 (en) | 2022-11-03 |
| KR20240044386A (ko) | 2024-04-04 |
| EP4330249A1 (en) | 2024-03-06 |
| CN117751106A (zh) | 2024-03-22 |
| IL308035A (en) | 2023-12-01 |
| AU2022264579A1 (en) | 2023-12-14 |
| JP2024517769A (ja) | 2024-04-23 |
| US20250230140A1 (en) | 2025-07-17 |
| MX2023012830A (es) | 2024-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022034568A1 (en) | Triazole-pyridinyl substituted azacyclohexyl acetic acid compounds as lpa receptor antagonists | |
| US20240109891A1 (en) | Novel substituted tricyclic aza-heterocycles as sos1 inhibitors | |
| AU2021264916A1 (en) | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | |
| CA3218258A1 (en) | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2h-pyranyl acetic acid compounds as lpa antagonists | |
| AU2014362231A1 (en) | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology | |
| CA2731432A1 (en) | Tri-cyclic pyrazolopyridine kinase inhibitors | |
| US20240109887A1 (en) | Novel substituted bicyclic aza-heterocycles as sos1 inhibitors | |
| WO2022165513A1 (en) | Cdk2 inhibitors and methods of using the same | |
| CA2916468A1 (en) | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | |
| CA3225439A1 (en) | Cdk2 inhibitors and methods of using the same | |
| WO2019169539A1 (en) | Novel oxa-and aza-tricyclic 4-pyridone-3-carboxylic acid for treatment and prophylaxis of hepatitis b virus infection | |
| WO2023056264A1 (en) | Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| AU2020395741C1 (en) | Substituted imidazolecarboxamide as Bruton's Tyrosine Kinase inhibitors | |
| US12338255B2 (en) | Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity | |
| HK40102702A (zh) | 作为lpa拮抗剂的新型三唑-吡啶取代的吡咯烷基和四氢-2h-吡喃基乙酸化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250428 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250428 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260401 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260401 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260422 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260422 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260422 |